The delayed onset of type 2 diabetes of six years or more significantly reduces the risk of cardiovascular disease and microvascular disease

SAN FRANCISCO, June 9, 2019 / PRNewswire / – People whose glucose tolerance is impaired can significantly reduce their risk of cardiovascular disease and microvascular disease by delaying the onset of type 2 diabetes for at least six years or by returning to a normal state. glucose tolerance as a whole, according to the study, "Early progression to diabetes or a regression to normal glucose tolerance in individuals with impaired glucose tolerance has long-term effects on the results. Long-Term: Follow-up after Thirty Years of Da Qing's Diabetes Study, Presented Today's 79th Scientific Sessions® of the American Diabetes Association® (ADA) at Moscone Center's San Francisco.

People with IGT have a much higher risk of developing T2DM and an increased risk of CVD and microvascular disease compared to those with normal glucose tolerance. The Da Qing Diabetes Prevention Study (DQDPS) showed that 90% of IGT participants in the non-intervention group had developed diabetes over a 20-year period. However, the magnitude of the increased risk that can be directly attributed to the onset of diabetes has been increased. not clear.

To badess this risk, the researchers performed a secondary badysis of the DQDPS. The initial study recruited 540 adults in China with IGT who were randomly badigned to participate in a lifestyle intervention (diet or exercise, or both) for six years. At the end of the study, participants were badessed to determine who had developed diabetes, had normal glucose tolerance, or had stayed with IGT. In 2016, 30 years after the start of the study, researchers conducted a follow-up study to badess the number and proportion of participants who developed CVD (defined as a non-fatal stroke or stroke). fatal, myocardial infarction or heart failure) and microvascular disease. (defined as the first appearance of severe retinopathy, nephropathy or neuropathy).

The results of the badysis revealed that of the 252 adults who developed diabetes, 65.6% developed cardiovascular disease and 44.3% developed microvascular disease; of the 114 who remained with IGT, 50.6% developed cardiovascular disease and 31.2% developed microvascular disease; Of the 174 who found normal glucose tolerance, 46.1% developed cardiovascular disease and 23.1% developed microvascular disease. Overall, the incidence of CVD and microvascular disease was 69% higher in people with GIT who had developed diabetes.

As a result, the researchers concluded that delaying the onset of diabetes in people with GIT six years or older resulted in decreased rates of complications and reduced the occurrence of cardiovascular and microvascular diseases.

"We know that people with impaired glucose tolerance are at high risk of developing diabetes and other complications," said the study's author. Guangwei Li, MD, honorary director of the International Medical Center of the Sino-Japanese Friendship Hospital; and director of the Center for Endocrinology and Cardiovascular Diseases of the Fuwai Hospital National Center of Cardiology of the Chinese Academy of Medical Sciences. "Our study clearly shows that reversing or delaying the onset of diabetes in people with GIT six years or older significantly reduces their risk of developing long-term complications such as CVD and microvascular disease. Essentially, the longer progression of diabetes can be delayed, the fewer complications. "

To speak with Dr. Li, please contact the ADA Press Office at the following address: From San Francisco Moscone Convention Center on June 7-11, by phone at 415-978-3606 or by email at [email protected].

The 79th Scientific Sessions of the American Diabetes Association, the world's largest scientific meeting dedicated to diabetes research, prevention and care, will take place June 7 to 11, 2019at the Moscone Center in San Francisco, California. Nearly 15,000 physicians, scientists, health professionals and industry representatives from around the world are expected to meet at scientific sessions to present cutting-edge research, treatment recommendations and advances in diabetes control. During this five-day meeting, participants will receive exclusive access to more than 850 presentations and 2,000 original research presentations, engage in stimulating and engaging discussions with leading diabetes experts, and obtain training credits. Continuing Education (FMC) or Continuing Education (CE). for educational sessions. The program is divided into eight thematic areas: Acute and Chronic Complications; Behavioral medicine, clinical nutrition, education and exercise; Clinical / Therapeutic Diabetes; Epidemiology / genetics; Immunology / Transplantation; Action of insulin / molecular metabolism; Integrated Physiology / Obesity; and islet biology / insulin secretion. Gretchen Youssef, MS, RDN, CDE, Chair of Health Care and Education, will deliver her speech entitled "It's all about access!", The Saturday, June 8, and Louis H. Philipson, MD, PhD, FACP, President of Medicine and Science, will give his lecture entitled "Precision Medicine – Addressing the Multiple Facets of Diabetes", the Sunday, June 9. Join the conversation of scientific sessions on social media using # ADA2019.

About the American Diabetes Association
Every day, more than 4,000 people are diagnosed with diabetes in America. Nearly 115 million Americans have diabetes or prediabetes and are striving to manage their lives while living with the disease. The American Diabetes Association (ADA) is the country's leading volunteer health organization that fights to counter the diabetes epidemic and help people living with diabetes to flourish. For nearly 80 years, the ADA has been leading discoveries and research to treat, manage and prevent diabetes while working tirelessly for healing. We help people with diabetes to thrive by fighting for their rights and developing programs, advocacy and education to improve their quality of life. Diabetes has brought us together. What we do next will make us connected for life. For more information or to get involved, visit our website at diabete.org or call 1-800-DIABETES (1-800-342-2383). The information is available in English and Spanish. Join the fight with us on Facebook (American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn).

153-OR Early progression to diabetes or regression to normal glucose tolerance in individuals with impaired glucose tolerance has an impact on long-term outcomes: 30-year follow-up of the patient's prevention study Di Qing diabetes

Briefing: Prevention of Type 2 Diabetes, Saturday, June 8, 11.45 – 12.45 PT

Session type: Oral presentations
Location: W-2022 (West, Level 2)
Session time: Sunday, June 9, 2019, 08:00 – 10:00

YANYAN CHEN, PING ZHANG, JINPING WANG, QIUHONG GONG, YALI AN, EDWARD GREGG, PETER H. BENNETT, GUANGWEI LI, Pekin, China, Atlanta, Georgia, Daqing, China, Phoenix, AZ

Context: People with GIT, a form of prediabetes, have a much higher risk of developing diabetes and a higher risk of developing cardiovascular and microvascular disease compared to people with normal glucose tolerance; However, the magnitude of the increased risk that may be directly attributable to the onset of diabetes is not clear.

The methods: The researchers conducted a secondary badysis of the 1986 Da Qing Diabetes Prevention Study (DQDPS), which identified 540 Chinese adults with IGT who participated in a six-year lifestyle intervention trial. At the end of the trial, participants were badessed to determine the number and proportion of those who had developed diabetes, regressed to normal glucose tolerance, or remained with IGT. In 2016, 30 years after the start of the trial, the researchers conducted a follow-up study to badess the number and proportion of people who developed CVD (defined as a nonfatal or fatal stroke, a heart attack myocardial or heart failure) and microvascular disease severe retinopathy, nephropathy or neuropathy).

Results: Of the 252 adults who developed diabetes, 65.6% developed cardiovascular disease and 44.3% developed microvascular disease; of the 114 who remained with IGT, 50.6% developed CVD and 31.2% developed microvascular disease; Of the 174 who found normal glucose tolerance, 46.1% developed cardiovascular disease and 23.1% developed microvascular disease. Overall, the incidence of CVD and microvascular disease was 69% higher in people with GIT who had developed diabetes.

conclusions: Delaying the onset of diabetes in people with GIT six years of age or older results in lower rates of complications and reduces the development of cardiovascular and microvascular diseases.

Disclosure of the author: Y.Chen: No. P.Zhang: No. J.Wang: No. Q.Gong: No. Y.An: No. E.Gregg: No. P.H. Bennett: No. G.Li: No.

SOURCE American Diabetes Association

Related Links

http://www.diabetes.org